The anticoagulant action of certain cations, particularly some of the lanthanides, has been known for forty years (2) (3) (4) (5) (6) , and one of them, neodymium, has been used as an antithrombotic agent (4, (6) (7) (8) (9) (10) (11) . Little is known about the related actinides, such as uranium and thorium. Our interest in thorium derived from studies on the untoward effect of the endotoxin-induced generalized Shwartzman phenomenon on thromboplastin generation (12) . Since colloidal thorium dioxide (Thorotrast) can induce the Shwartzman phenomenon (13, 14) , and since disturbed coagulation and hemorrhagic phenomena have been observed after its administration (12, 14) , its precise effect on coagulation was explored. Interference with clotting both in vivo and in zitro was so marked and specific as to warrant extension of the study to the related elements, lanthanum, neodymium, cerium, and uranium. As a consequence, a hitherto unrecognized clotting factor has been disclosed that is especially vulnerable to this group of elements and essential for the earliest phase of coagulation, the elaboration of intrinsic blood thromboplastin. The factor has been separated from other known coagulation components, and some of its properties are reported in this communication. An accompanying paper describes an assay method and variations of the factor in health and disease. The effect of this unique group of elements draws attention to the vast and as yet unexplored area relating atomic structure of cations to biologic activity of certain proteins.
* Submitted for publication June 4, 1963 Clotting time. This was measured by the orthodox Lee-White procedure, employing three clotting tubes and taking the clotting time of the third tube as the end point.
Platelet count. Platelets were enumerated as described by Ham (20) , using Rees and Ecker diluting fluid. In our laboratory normal human blood contains 200,000 to 300,000 per mm by this method.
Thorium vnlnerable factor in serum (TVF) was assayed by a procedure described in the accompanying second paper of this series (21) .
Starch gel electrophoresis of a purified serum preparation was performed as previously described (22) .
Column chromatography. A slurry of DEAE, prepared as recommended by Peterson and Sober (23) , was poured into a chromatography tube (2 X 33 cm), filtered through a sintered glass disc of coarse porosity, and then packed with air pressure to give a 25-cm column. Two L of sodium phosphate buffer (0.005 M), pH 7.0, was passed through the column under a hydrostatic head of about 3 feet at a flow rate of 40 ml per hour. Four ml of a purified serum fraction containing a total of 52 mg protein was adsorbed onto the column under gravity, and the top of the column was (19) . Thorotrast added to a sample of preinfusion blood in vitro (1.5 ml per 100 ml blood) produced almost the identical TGT abnormalities.
1-ml portions of the buffer, which was subsequently used as an eluting agent for the first 30 effluent fractions comprising 7 ml each. This was followed by a variable gradient eluant 13 flowing from a 250-ml mixing chamber initially filled with 0.005 M sodium phosphate buffer, pH 7.0, connected to a superiorly suspended reservoir containing 0.4 M sodium acetate and 0.05 M sodium phosphate buffer, pH 7.0. The first protein peak emerged at the thirty-ninth effluent fraction. At the fiftieth fraction, the reservoir was changed to contain 0.4 M sodium acetate and 0.05 M sodium phosphate, pH 5.2. The second protein peak emerged at tube 53. The protein concentrations were determined spectrophotometrically by absorption at 280 g. The results were expressed in terms of Kjeldahl nitrogen and recalculated in terms of protein, using the nitrogen to protein ratio found in the purified serum preparation used as the starting material. The specific bilogical activity was expressed as percentage of coagulation factor per milligram protein.
Results
The infusion into a rabbit of 1.6 ml of Thorotrast per kg body weight 14 promptly caused a 13 These conditions for variable elution were found optimal by trial and error.
14An amount which is one-half that generally used as a priming dose (3.0 ml per kg) or as single dose (4.0 ml per kg) to induce the generalized Shwartzman phenomenon (14) . marked abnormality in thromboplastin generation ( Figure 1 3 .3%o, and almost total inactivation at 6.7%o.
Since the effect on human and rabbit blood ap- 15 In these, and all other experiments not aimed at elucidating rates of inactivation, the Thorotrast (or related elements) was added to serum immediately before its use in the TGT. Thus, the serum was only momentarily exposed to the full concentrations indicated and subsequently exposed for the duration of the incubation time of the TGT, at a considerably lower concentration determined by the concentration of serum in the incubation mixture. peared identical, further study was confined to human material. Inasmuch as both plasma and serum seemed affected, each was studied separately. In plasma, progressive inactivation of Factor V to one-third its original level occurred Incubation mixture contained Inosithin, normal human BaSO4-adsorbed oxalated plasma, and the various sera indicated. Respective sera were mixed 1: 1, and the combination was then diluted with buffer in the usual manner for the TGT. within 25 minutes after Thorotrast (Table I) . This was associated with slight prolongation of the prothrombin time, but the actual concentrations of Factors II and VII (Owren) 18 remained unchanged.
As will become evident below, a serum component was also adversely affected. To explore the possibility that the plasma and serum entities were identical, experiments were performed in which thorium-treated plasma was admixed with plasma treated with BaSO4 which, as found by prior experience, adsorbs the thorium-vulnerable factor from serum. The data (Table II) indicate that BaSO4 plasma corrects the thorium induced plasma defect. Since, however, BaSO4-adsorbed serum fails to correct the thorium-induced serum abnormality, it is concluded that the serum defect is distinct from the plasma abnormality. Moreover, in experiments not included, the addition or presence of oxalate or citrate in plasma failed to prevent or reverse thorium inactivation, in contrast to serum (see below).
The nature of the serum entity adversely affected was first explored by performing crosscorrection experiments with sera from patients with specific coagulation defects. Factors IX (PTC), X (Stuart), and XI (PTA) were readily excluded, since the defective TGT obtained with sera derived from patients deficient in these specific entities was corrected when admixed with thorium-treated serum, and vice versa (Figures 2, 3, and 4) . Moreover, Factor XII could be excluded, since BaSO4 normal plasma, used in the TGT to demonstrate serum defects, contains 16 These include both Factors VII and X, as mentioned above in Methods. determine whether the adverse effect of Thorotrast 18 was referable to its colloidal nature or to the small amount of thorium existing in cationic form. Thorium chloride-treated serum failed to correct the abnormality in Thorotrasttreated serum, indicating the identity of the defect. On a molar basis the chloride was 50 times more potent than the dioxide. The induced defect was proportional to ThC14 concentration ( Figure 5 ), and progressive ( Figure 6 ).
Some physicochemical characteristics of the serum TVF were defined. It is adsorbed by BaSO4 (100 mg per ml serum) from which it is elutable by concentrated citrate solutions (25%o); it is found in the serum proteins precipitated between 50 to 66% (NH4)2SO4 saturation, and it is relatively labile. Serum maintained at 0 to 40 C for 21 days fails to correct the thorium induced defect; at 370 C the TVF activity decreases markedly within 2 hours, at 500 C within 20 minutes (Figure 7 ). Stability is enhanced by 18 Dextrin, the other component of commercial Thorotrast, was inert. INCUBATION TIME MINUTES fect by oxalate or citrate, a question arises as to whether the abnormality induced in serum, in contrast to that in plasma (Factor V inactivation), may be referable to the presence of anticoagulant oxalate (0.02 M concentration) in the plasma. An experiment was performed 20 to explore this. ThCl4 was added to normal oxalated plasma (final concentration, 6 X 104 M), the combination was kept at room temperature for 2 hours, then recalcified with an equal volume of 0.02 M CaC12 solution. Fifteen minutes after coagulation, which required 5 to 7 minutes to occur, the clotted tube was centrifuged for another 10 minutes (room temperature), and the supernatant serum was tested in the TGT side by side with its counterpart derived from recalcified untreated plasma. In contrast to normal thromboplastin generation obtained with the latter, the serum derived from the thorium-treated oxalated plasma was impaired. It thus appears that the TVF, demonstrable in serum, is not only present in plasma but also vulnerable to this element despite the presence of oxalate under the conditions described.
The source of lipid in the TGT appeared important. When platelets replaced Inosithin, the incubation mixture containing thorium-treated serum showed normal generation (Figure 9 ), suggesting that platelets might be providing TVF. Platelets pretreated with Thorotrast (in amount 20 By Dr. Araceli Engel. 6 7 8 9 10 11 12 13 the adsorbate was eluted with 25% sodium citrate and dialyzed. The fraction which precipitated at 50 to 66% ammonium sulfate concentration was dialyzed, and then subjected to electrophoresis on starch gel in borate-Tris-EDTA buffer, pH 8.6. 0.4-to 0.6-ml samples were placed in a 7-mm wide slot 7.5 cm from the end of the starch gel block of 30-cm total length; current was applied for 18 hours at 9°C and 200 v. The material expressed and eluted from each segment was assayed by procedures described in Methods. The experiment depicted is typical of several similarly performed. Particularly noteworthy are segments 8, 9, and 10. The material expressed was rich in TVF activity yet devoid of Factor VII activity and Factor X (as measured with Stypven). Factors IX and XI were not determined. plasma (not shown) and serum ( Figure 10) and at approximately the same concentration (3 X 10-4 M) ; admixtures of thorium-treated serum or plasma with their neodymium-treated counterparts were still inactive. All the elements acted the same on serum. Uranium 21 chloride (UCl14) also produced the same serum defect (not shown), but uranyl nitrate [U02(N03)2] was inert in similar concentrations. The unrelated element, zinc (ZnCl2, 3 x 10-4 M in serum) was also inert 22 (not shown).
Certain clotting factors (VII and X), existing in plasma or serum as proenzymes, can be markedly activated by the proteases trypsin and papain (25, 26) . Similarly, when trypsin was added to normal serum, more than threefold enhancement of TVF activity occurred (Figure 11 ), suggesting that TVF may exist to a considerable extent in serum as a relatively inert zymogen, analogous to Factors VII and X.
Partial separation of TVF from Factor VII was achieved by starch gel electrophoresis (Figure 12) . Although some overlapping of activity generally occurred, fractions were obtainable which contained TVF without Factors VII, X, or any other clotting factor activity. Similarly, with DEAE columns a large peak of protein was obtained rich in TVF and uncontaminated by Factors VII, X, or IX ( Figure 13 ). These (27) (28) (29) , can explain the hemorrhagic phenomena consequent to thorium administration (14) . In vitro, the element rapidly inactivates Factor V in plasma, and impairs thromboplastin generation. Factors I, II, VII, VIII, IX, X, XI, and XII, all plasma constituents, are unimpaired.
In serum thorium affects an entity, for the time being designated TVF, that is essential for thromboplastin generation and that appears to be distinct from clotting constituents present also in serum-Factors VII, IX, X, XI. and XII. Like the first three, TVF is adsorbed by BaSO4, from which it can be eluted by citrate. It is precipitated at 50 to 66%o (NH4) 2SO4 saturation, in contrast to Factor XI (25 to 33%) (30), Factor IX (33 to 50%o) (30) , and Factor XII (25 to 40%o) (31) . Its relative instability also distinguishes it from Factors VII, IX, X, XI, and XII (31) (32) (33) (34) (35) (36) (37) .
TVF appears also to be distinct from other more recently described and less well defined serum clotting entities. The "prephase accelerator" (PPA) of Duckert, Straub, and Yin (38) (39) (40) is destroyed at 500 C, but, unlike TVF, it is stable at 40 C for many months. Moreover, Factor IX-deficient serum, said to be lacking in PPA also, corrects the thorium-induced defect. Also separable from other coagulation factors by physicochemical means, it is thought to function as an accelerator of the formation of intermediate product I of intrinsic thromboplastin (39) . Nevertheless, from the disparate stability characteristic, we must conclude that TVF is not PPA.
Since thorium-treated serum retains the STA activity of Wessler and Reimer (41) , TVF must also be distinct from this moiety. This consideration similarly applies to activation product of Henderson and Rapaport (42) . This entity, thought to arise from the interaction of Factors XII and XI, has a powerful thrombotic activity when injected intravenously, thus strongly resembling STA.
Less readily distinguishable is TVF from the recently described labile serum fraction of Connor, Warner, and Carter (43) , an entity required for normal thromboplastin generation, and with properties remarkably similar to some of those of TVF. Abnormality in this substance was observed in some subjects with unexplained hemorrhagic diathesis, in the newborn, in bishydroxycoumarin (Dicumarol)-treated subjects, and in patients with liver disease. As is reported in the accompanying paper of this series (21), these clinicolaboratory characteristics were also found with TVF. The relationship, if any, between these factors must await further study.
Duckert, Fluckiger, and Koller (44) described an entity deficient in aged serum, which they originally called "Factor X." Except for its relative lability, in most properties this factor resembled what was later described as Stuart Factor (Factor X) (33) , which is stable. Whether this substance is identical with TVF remains to be clarified. TVF might constitute the activated form of a relatively inert precursor in plasma, e.g., Factor IX or X, rather than a distinct new entity. This possibility is difficult, if not impossible, to accept, since sera from subjects deficient in the activity of these factors (whether due to inadequacy of precursors or activated forms) were able to rectify the TVF-defective sera. Moreover, they had full TVF activity determined by the TVF assay procedure (21) . Other distinguishing features are also to be noted: dissociation in response to coumarin therapy as well as in the blood in pregnancy (21) . Of additional interest is the observation (not shown) that the addition of Thorotrast to a normal human blood generating mixture at the point of maximal generation (7-minute incubation) was followed by rapid decay of the evolved thromboplastic activity (12) , suggesting prompt cessation of further thromboplastin generation.
Thus, the data indicate a new serum factor distinguishable from other factors by its lability, by the ability of the thorium-treated serum to correct the disturbed coagulation associated with all other known defects, and by its separability from other clotting constituents by physicochemical means. Further activation of this factor by trypsin suggests that in plasma the substance may exist in an inert precursor form, as do many other coagulation factors.
Of further interest is the correction of the thorium-induced serum defect by substituting platelets for Inosithin, which is generally used as a source of lipid in the thromboplastin generating mixture. Thrombocytes are known to contain certain plasma and serum coagulation components such as Factor V, in large amounts, and Factors VII, VIII, IX, and I in smaller amounts (45) . Conceivably platelet correction of the thorium defect is due to TVF adsorbed on the platelet surface. This interpretation is supported by the fact that neither thorium-treated serum and normal platelets, nor thorium-treated platelets and normal serum, exhibit defective thromboplastin generation, but that when both serum and platelets are exposed to thorium, thromboplastin generation is impaired. The failure of thorium to induce a defect by treatment of platelets alone suggests that there is prior absorption or binding of thorium by platelets, preventing its release into the generating mixture.
The addition to serum of another actinide, uranium, or the related lanthanides, neodymium, cerium, and lanthanum, produced a defect identical to that produced by thorium. These elements have remarkably similar arrangement of their valence electrons, and, as would be expected, they have many chemical properties in common. They do not ionize to any great extent in solution, but are very prone to form co-ordination compounds of great stability because of their high charge (oxidation state) and relatively small ionic radius (46, 47) . Accordingly, they chelate readily by utilizing the available orbital of the penultimate electron shell. An example is the thorium trichelate of the structure: NH4 NH4 CHART 1 Conceivably, these similar elements could complex with certain biologically functional amino groups of a protein. Indeed, strong complexing ability of rare earth elements with proteins in vivo (48) and in vitro (49, 50) has already been demonstrated. The failure of uranyl nitrate [UO2(NO3)2] to produce a clotting defect might be due to its inability to form such complexes, since four of its available co-ordinate bonds are already linked to oxygen.
Such chelation could promptly and progressively deform a clotting protein, thus altering its biologic behavior. This effect might be reversible if the thorium could somehow be removed from the protein. 2) The plasma defect consists of progressive inactivation of Factor V.
3) The serum defect involves an entity distinct from any hitherto known clotting factor or intermediate. It is adsorbable by BaSO4, elutable by citrate, and it is demonstrable in the protein fraction precipitated at 50 to 60% (NH4)2SO4. The vulnerable factor in serum (TVF) is relatively labile, has been separated from the other coagulation factors by physicochemical means, and can be markedly activated by trypsin. 4) Replacing Inosithin by normal platelets in the thromboplastin generation mixture corrects the thorium-induced defect. In contrast, thorium-treated platelets are inert.
5) Citrate and oxalate completely reverse the thorium-induced defect, but EDTA is ineffective.
6) It is suggested that the lanthanides and actinides produce a defect in serum by forming a reversible complex with a serum protein, which is a hitherto unrecognized clotting factor necessary for thromboplastin generation. The mechanism by which the biologic function of this protein is comprised by this group of elements, structurally similar atomically, appears to be reversible chelation at specific sites on the protein essential for its clotting activity.
